Provider of infection-prevention/sterilization products and services for hospitals and medtech manufacturers.
Provider of infection-prevention/sterilization products and services for hospitals and medtech manufacturers.
Earns a mix of one-off equipment sales to hospitals, recurring consumables and service contracts on installed equipment, and per-load fees where device makers pay to have products sterilised in its plants. The contract-sterilisation arm came with the 2015 purchase of Synergy Health. It is incorporated in Ireland but run from Ohio.
Moat: narrow (regulatory licence, switching costs, installed base). Outsourced sterilization requires regulatory-validated facilities that are costly and slow to replicate.
Headquarters: Dublin, Ireland (US operations Mentor, Ohio) · Founded: 1985 · Employees: 17,937
Size Steris (STE) is a United States Health Care company (Medical Specialties) with a market value of $25.2B, the 425th largest of 3,085 United States companies the cockpit tracks. Shares closed at $259.57 on 18 Nov 2026.
Performance Over six months the shares gained 20.6%, against +28.2% for the median peer and -2.2% for the United States market (cap-weighted) — 7th lowest of 21 in its peer set.
Growth Revenue grew 8.1% over the last twelve months (peer median +6.7%); the operating margin is 20.0% (peer median 18.2%).
Valuation It trades at 21.9× forward earnings against a peer median of 28.0× (6th cheapest of 20).
Price implies For today's price to make sense, revenue must grow about 14% a year for seven years (Req g). Recent delivered growth is +14%, so the hurdle is +0 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 2.0 points above its cost of capital (9.1% WACC).
Backlog Backlog (remaining performance obligations) was $1.53B at 30 Sep 2026, down 20% on a year earlier — 0.2 years of trailing revenue. Backlog detail →
Credit Steris has 2 bonds outstanding ($1.35B), rated BBB by the agencies and trading like A- at a weighted spread of 86 bp.
Short interest Short interest is 2.2% of the free float (30 Oct 2026).
Next results Next results expected around 10 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $6.17B | $5.94B | $5.46B | $5.14B | $4.54B |
| Revenue growth | — | +9% | +6% | +13% | — |
| Gross profit | $2.79B | $2.66B | $2.42B | $2.24B | $1.98B |
| EBITDA | $1.73B | $1.63B | $1.46B | $1.47B | $1.36B |
| Net income | $827M | $782M | $629M | $378M | $107M |
| Free cash flow | $937M | $972M | $776M | $613M | $395M |
| Capital expenditure | $352M | $369M | $370M | $360M | $362M |
| Total debt | $2.05B | $2.09B | $2.20B | $3.38B | $3.25B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Steris STE | $25.2B | +21% | +8% | 20% | 21.9× | 14.0% |
| Sotera Health SHC | $4.65B | +5% | +7% | 37% | 15.7× | 14.4% |
| Getinge GETI-B.ST | $7.45B | +40% | -4% | 14% | 21.1× | 5.0% |
| Ecolab ECL | $84.3B | +21% | +9% | 18% | 33.6× | 20.3% |
| Stryker SYK | $121B | -1% | +8% | 25% | 19.9× | 10.7% |
| Fortive FTV | $19.9B | +13% | -22% | 20% | 20.4× | 18.0% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | STE | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +15.3% | +5.7% | 3rd highest of 21 |
| 6-month return | +20.6% | +28.2% | 7th lowest of 21 |
| Distance from 52-week high | -3.1% | -8.4% | 4th highest of 21 |
| Revenue growth (TTM) | +8.1% | +6.7% | 9th highest of 21 |
| Operating margin | 20.0% | 18.2% | 10th highest of 21 |
| Forward P/E | 21.9× | 28.0× | 6th cheapest of 20 |
| Growth the price implies (Req g, 7 yrs) | 14.0% | 16.2% | 9th least demanding of 18 |
| Growth delivered (Del g) | +13.8% | +7.4% | 2nd highest of 18 |
| Hurdle (Req g minus delivered) | +0.2 pp | +4.2 pp | 6th least demanding of 18 |
| ROIC minus cost of capital | +2.0 pp | +3.2 pp | 10th lowest of 21 |
| EV / EBITDA | 15.5× | 20.8× | 6th cheapest of 17 |
| Net debt / EBITDA | 0.9× | 1.5× | 7th least indebted of 17 |
| Bond spread | 86 bp | 90 bp | 4th tightest of 9 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Steris STE | United States | $25.2B | +21% | +8% | 20% | 21.9× | 14.0% | +13.8% |
| Sartorius Stedim Biotech DIM.PA | France | $24.2B | +32% | +4% | 19% | 45.7× | 33.4% | +9.2% |
| Terumo 4543.T | Japan | $24.0B | +32% | +15% | 17% | 27.8× | 8.8% | +13.0% |
| West Pharmaceutical Services WST | United States | $28.1B | +32% | +13% | 23% | 40.2× | 25.8% | +7.4% |
| Dexcom DXCM | United States | $30.8B | +16% | +13% | 24% | 28.0× | 19.6% | +19.3% |
| Straumann STMN.SW | Switzerland | $20.4B | +20% | +2% | 21% | 32.9× | 16.2% | +12.8% |
| Illumina ILMN | United States | $31.8B | +48% | +6% | 21% | 35.2× | 27.2% | +6.0% |
| Sartorius SRT.DE | Germany | $19.9B | +26% | +4% | 18% | 43.0× | 25.6% | +8.7% |
| Sonova SOON.SW | Switzerland | $19.8B | +40% | -6% | 23% | 25.3× | 6.0% | +6.7% |
| Guardant Health GH | United States | $19.6B | +26% | +42% | -39% | n/a | n/a | n/a |
| Zimmer Biomet ZBH | United States | $19.6B | +21% | +7% | 16% | 11.7× | 7.4% | +3.2% |
| Shenzhen Mindray Bio-Medical Electronics 300760.SZ | China | $33.6B | +15% | +5% | 28% | 27.3× | 1.0% | +9.7% |
| ResMed RMD | United States | $34.1B | +16% | +9% | 34% | 19.7× | 5.7% | +12.1% |
| Mettler Toledo MTD | United States | $34.6B | +60% | +7% | 29% | 33.7× | 20.1% | +5.5% |
| Alcon ALC.SW | Switzerland | $36.9B | +18% | +1% | 12% | 21.5× | 12.2% | +6.1% |
| Revvity RVTY | United States | $17.0B | +61% | +5% | 16% | 26.2× | 26.4% | -5.5% |
| GE HealthCare GEHC | United States | $37.8B | +30% | +7% | 14% | 15.6× | 5.0% | +3.7% |
| Coloplast A/S COLO-B.CO | Denmark | $16.6B | +24% | +4% | 25% | 20.0× | -2.1% | +8.3% |
| Shanghai United Imaging Healthcare 688271.SS | China | $14.4B | +4% | +27% | 9% | 45.7× | n/a | n/a |
| Waters WAT | United States | $45.8B | +37% | +81% | 10% | 29.1× | 48.1% | +6.0% |
| Glaukos GKOS | United States | $13.8B | +62% | +47% | -9% | 161.5× | n/a | n/a |
Steris has 2 bonds outstanding with $1.35B face value. The agencies rate it BBB; its bonds trade like A-. Weighted yield 5.95%, a spread of 86 bp over government bonds.
Steris reported $1.53B of remaining performance obligations at 30 Sep 2026, down 20% from a year earlier and down 0% from the previous quarter. That is 0.2 years of trailing revenue already under contract. Book-to-bill last quarter: 1.00.